PT  - JOURNAL ARTICLE
AU  - KOSHIRO MORINO
AU  - SATORU SEO
AU  - TOMOAKI YOH
AU  - HIROTO NISHINO
AU  - KENYA YAMANAKA
AU  - KEN FUKUMITSU
AU  - TAKAMICHI ISHII
AU  - KOJIRO TAURA
AU  - HIDEAKI OKAJIMA
AU  - TOSHIMI KAIDO
AU  - SHINJI UEMOTO
TI  - The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma
AID  - 10.21873/anticanres.13329
DP  - 2019 Apr 01
TA  - Anticancer Research
PG  - 2155--2161
VI  - 39
IP  - 4
4099  - http://ar.iiarjournals.org/content/39/4/2155.short
4100  - http://ar.iiarjournals.org/content/39/4/2155.full
SO  - Anticancer Res2019 Apr 01; 39
AB  - Background/Aim: The impact of adjuvant chemotherapy (AC) for extrahepatic cholangiocarcinoma (ECC) remains unclear. This study evaluated the efficacy and limitations of AC. Patients and Methods: Between 2006 and 2016, 106 patients with stage II-IV ECC who underwent curative resection with biliary tract reconstruction were retrospectively analyzed. Patients were divided into two groups: Those who received AC (n=57) and those who did not (n=49). Results: Fewer grade 3-4 complications were observed in the AC group compared to the non-AC group (38.6 vs. 61.2%, p=0.03). In the non-AC group, complications were the most frequent reason for omitting AC (n=21, including 13 with biliary fistula). In the AC group, the therapy completion rate was 56.1% and the main reason for discontinuation was adverse events (n=12, including six with cholangitis). AC was not associated with survival benefits (median survival: 50.4 vs. 37.3 months, p=0.916). Conclusion: AC for ECC might be inadequate as a standard strategy due to the low implementation and completion rates because complications often hamper administration.